Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Balint syndrome is a rare neurologic disease characterized by the triad of optic ataxia, ocular apraxia and simultanagnosia due to posterior parietal lobe lesions. Patients report ophthalmologic difficulties in the absence of underlying ophthalomologic anomalies and present severe visual and spatial disabilities in locating and reaching objects, initiating voluntary eye movements and perceiving more than one object at a time.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for Balint syndrome.
106 publications have been identified in PubMed for Balint syndrome. Kisho has analyzed 43 by research type. Research spans Review / Meta-Analysis (33%), Case Report / Case Series (26%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 14 | 33% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 9:39 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Balint syndrome
Patient case studies
11 |
26% |
Disease patterns and progression | 7 | 16% |
Clinical study results | 5 | 12% |
Laboratory research | 5 | 12% |
Other research | 1 | 2% |
Zhao CS (2026). [PMID: 41608829](https://pubmed.ncbi.nlm.nih.gov/41608829/). *Curr Opin Ophthalmol*. [Review / Meta-Analysis]
Billet N (2026). [PMID: 41850923](https://pubmed.ncbi.nlm.nih.gov/41850923/). *Rev Neurol (Paris)*. [Other]
Changlai T (2025). [PMID: 40621301](https://pubmed.ncbi.nlm.nih.gov/40621301/). *Cureus*. [Case Report / Case Series]
Nguyen T (2025). [PMID: 39971096](https://pubmed.ncbi.nlm.nih.gov/39971096/). *Prog Retin Eye Res*. [Review / Meta-Analysis]
García DM (2025). [PMID: 40409801](https://pubmed.ncbi.nlm.nih.gov/40409801/). *Adv Genet*. [Review / Meta-Analysis]
Liu Z (2025). [PMID: 40633646](https://pubmed.ncbi.nlm.nih.gov/40633646/). *Exp Eye Res*. [Basic Science / Preclinical]
Ghoraba HH (2025). [PMID: 39837650](https://pubmed.ncbi.nlm.nih.gov/39837650/). *Clin Exp Ophthalmol*. [Review / Meta-Analysis]
Safonova TN (2025). [PMID: 40353541](https://pubmed.ncbi.nlm.nih.gov/40353541/). *Vestn Oftalmol*. [Clinical Trial Publication]
Arita R (2025). [PMID: 39920919](https://pubmed.ncbi.nlm.nih.gov/39920919/). *Ocul Surf*. [Clinical Trial Publication]
He Y (2025). [PMID: 40545016](https://pubmed.ncbi.nlm.nih.gov/40545016/). *Am J Ophthalmol*. [Clinical Trial Publication]
AI-curated news mentioning Balint syndrome
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.